IL-20 in rheumatoid arthritis

Research output: Contribution to journalReview articlepeer-review

9 Citations (Scopus)

Abstract

Rheumatoid arthritis, a systemic autoimmune disease, causes chronic joint inflammation and bone destruction. Interleukin (IL)-20's association with this disease, and its expression and regulation has been extensively studied since 2006. Anti-IL-20 antibody has paved the way to clinical trials aimed at blocking the pathogenic actions of IL-20 in rheumatoid arthritis. This review focuses on current knowledge of IL-20's involvement in the pathogenesis of rheumatoid arthritis.

Original languageEnglish
Pages (from-to)960-964
Number of pages5
JournalDrug Discovery Today
Volume22
Issue number6
DOIs
Publication statusPublished - 2017 Jun

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Drug Discovery

Fingerprint Dive into the research topics of 'IL-20 in rheumatoid arthritis'. Together they form a unique fingerprint.

Cite this